For detailed cost planning across your full protocol, the peptide cost calculator can help you estimate total expenses based on your dose schedule and vial count
The aim of this study is to assess PE-A5% as a treatment for patients with ACLF in a pivotal study Methods: A phase 3, multicenter, randomized (1:1), controlled, parallel-group, open-label study (APACHE) compares standard medical treatment (SMT) + PE-A5% (treatment arm) to SMT alone (control arm)
How about I, I, I, I speed down to less than two days
In the SURMOUNT-1 trial, patients lost an average of 15-21% of their initial body weight over 72 weeks, with results varying by dose and individual factors
JJH is a minority shareholder and board member of Antag Therapeutics and Bainan Biotech and has been a consultant for, has served on scientific advisory panels of, and has been speaker honoraria for Novo Nordisk and MSD/Merck